Evolva Holding SA

  • WKN: 2121806
  • ISIN: CH0021218067
  • Land: Schweiz

Nachricht vom 21.04.2021 | 07:01

Evolva Q1 2021 Trading Update

Evolva Holding SA / Key word(s): Miscellaneous

21-Apr-2021 / 07:01 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 KR
The issuer is solely responsible for the content of this announcement.


Reinach, April 21, 2021 - Evolva (SIX:EVE) today issues a trading update in respect to the period from January to March 2021.

Sales continued to progress well, with the trends and momentum described in our FY 2020 results on 25 February 2021. We are seeing a particularly strong performance in Health Ingredients driven by consumer trends, and weaker demand in Flavors and Fragrances, which is still impacted by the pandemic but with promising signs of recovery. Overall trading continues in line with our expectations.

We have made progress in scaling up and running manufacturing, with steady delivery of volumes of key products, which backed growth during the first quarter of the year. We are now in the process of further increasing capacity in our network of contract manufacturers. This will start to support our business in the second half of the year, in line with plans.

Oliver Walker, CEO of Evolva, said: «It would not be appropriate in the present pandemic to say that we look forward to the future with confidence, but we are in a favourable position. I remain grateful and proud of our people for their commitment and continued support from our customers.»

Disclaimer
This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not place undue reliance on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.

About Evolva
Evolva is a Swiss biotech company focused on the research, development and commercialization of ingredients based on nature. We have leading businesses in Flavors and Fragrances, Health Ingredients and Health Protection. Evolva's employees, half of which are women, are dedicated to make the best products that can contribute to health, wellbeing and sensory enjoyment. Find out more at
 evolva.com.

For Evolva multimedia content, please visit: evolva.com/multimedia-library/.

Contact
Barbara Duci
Head of Investor and Corporate Relations
+41 61 485 2003
+41 79 739 2636

barbarad@evolva.com



End of ad hoc announcement

show this

Event im Fokus

Termine 2021

10. Juni 2021:Fachkonferenz Immobilien

14./15. Juli 2021: Fachkonferenzen Beteiligungsgesellschaften & Consumer/Leisure

13./14. Oktober 2021: Fachkonferenzen Finanzdienstleistungen/Technologie

10./11. November 2021: Fachkonferenzen Software/IT & Branchenmix

„Je nach aktueller Covid-19 Situation und den bestehenden Vorschriften für Versammlungen entscheidet sich ca. 5 Wochen vor dem Termin, in welcher Form die Konferenzen stattfinden.“

GBC-Fokusbox

Kaufen: Vectron Systems AG legt verstärkt Fokus auf Digitalgeschäft

Nachdem die Vectron Systems AG bislang insbesondere Kassensysteme verkauft hat, wird nun das Digitalgeschäft stärker in den Fokus rücken. Damit sollen die wiederkehrenden Einnahmen und die Wertschöpfung je Kunde deutlich erhöht werden. Über Cloud-Module können die Kunden nun mehrere digitale Services, die sie sonst über viele Einzelverträge abdecken, direkt mit dem Erwerb der Vectron-Kassen über den Fachhandel dazubuchen. Wir haben die Vectron Systems AG im Rahmen eines DCF-Modells bewertet und ein Kursziel in Höhe von 21,15 € ermittelt und vergeben das Rating KAUFEN.

Aktueller Webcast

fashionette AG

Earnings Call Q1 2021

17. Juni 2021

Aktuelle Research-Studie

q.beyond AG

Original-Research: q.beyond AG (von Montega AG): Kaufen

17. Juni 2021